Eplontersen ATTR-CM Phase III Failure: TTR Silencing Mechanism Fails Where Stabilizers Succeeded

Wainua Fails Phase III ATTR-CM Trial, Stocks Plummet

AstraZeneca and Ionis Pharmaceuticals experienced significant stock drops on July 9, 2026, following the announcement that their Phase III CARDIO-TTRansform trial for Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint. The study, which evaluated Wainua against placebo over 140 weeks, did not demonstrate a statistically significant benefit on the composite outcome of cardiovascular mortality and recurrent cardiovascular clinical events, despite the drug being generally well tolerated.

• The CARDIO-TTRansform study, investigating Wainua in ATTR-CM, missed its primary composite endpoint of cardiovascular mortality and recurrent cardiovascular clinical events up to 140 weeks. Wainua, a gene silencer, did not provide a statistically significant benefit when added to standard of care, which included a majority of patients already on a stabiliser therapy.
• While the overall trial did not meet its primary objective, a prespecified subgroup analysis of patients treated with Wainua monotherapy showed a nominally significant reduction in primary composite events compared to placebo. The safety profile of Wainua was consistent with previous results, indicating that the treatment was generally well tolerated.
• The trial failure led to substantial financial repercussions for both companies; AstraZeneca's stock dropped 13% on the London Stock Exchange, and Ionis' stock fell 19% on the Nasdaq. This outcome is likely to bolster the market position of competing treatments, such as Alnylam's Amvuttra, Pfizer's Vyndamax, and BridgeBio's Attruby, in the ATTR-CM space.
• Analysts, including those from Jefferies, speculate that the high proportion of patients in the control group receiving Pfizer's Vyndamax may have influenced the trial results. Approximately 57% of control patients were on Vyndamax at baseline, increasing to nearly 80% by the end of the study, which is significantly higher than in comparable trials and could have obscured Wainua's potential benefits.

Unpacking the CARDIO-TTRansform Trial Design and Primary Endpoint Failure

The ATTR-CM clinical trial landscape spans over a decade of interventional research, encompassing TTR stabilizers, RNA-targeting silencers, and emerging amyloid-clearing agents across progressively larger and more methodologically refined phase 3 designs. A consistent temporal trend has been observed: patients enrolled in more recent trials present with earlier-stage disease, as evidenced by declining 12-month placebo-arm all-cause mortality rates across successive trials. The CARDIO-TTRansform trial, evaluating the RNA ligand conjugate eplontersen, represents the largest ATTR-CM interventional study to date, with 1,432 randomized participants and a design that permitted concomitant TTR stabilizer use.

ACM = all-cause mortality; mITT = modified intention-to-treat; OLE = open-label extension; SC = subcutaneous; CV = cardiovascular; LVEF = left ventricular ejection fraction; E/e' = ratio of early mitral inflow velocity to early diastolic mitral annular velocity.

Wainua's Established Safety Profile and Approved Indication

Across its studied indications, eplontersen (Wainua) has demonstrated a consistently favorable safety and tolerability profile. In the pivotal Phase 3 NEURO-TTRansform trial enrolling 144 adults with ATTRv amyloidosis with polyneuropathy — including 49 patients (34%) with concomitant cardiomyopathy — eplontersen was generally well tolerated over 65 weeks of treatment, with primary safety effects not significantly different from the control group. Phase 1 data from a randomized, placebo-controlled study in healthy volunteers further supports this profile: all enrolled participants completed treatment across multiple-dose cohorts (45, 60, and 90 mg) and a single-dose cohort (120 mg), with no serious adverse events reported. These findings were attributed in part to the productive receptor-mediated hepatocyte uptake afforded by the GalNAc conjugation, which confers approximately 50-fold and 30-fold increases in potency relative to unconjugated inotersen in human hepatocyte cell culture and humanized TTR-mutant mouse models, respectively — enabling lower and less frequent subcutaneous dosing every four weeks.

The tolerability advantage of eplontersen over its unconjugated predecessor inotersen is particularly well characterised in a switch study conducted within the NEURO-TTRansform programme. Of 24 patients initially randomised to inotersen, 20 (83%) transitioned to eplontersen at Week 37, with four discontinuing prior to the switch due to adverse events or investigator decision. Following the transition, treatment-emergent adverse events were recorded in 19 of 20 patients (95%) during eplontersen treatment (Weeks 37–85), compared with 24 of 24 patients (100%) during inotersen treatment (up to Week 35). Critically, mean platelet counts — which had declined substantially during inotersen treatment (mean nadir reduction of –40.7%) — recovered toward baseline following the switch to eplontersen (mean nadir reduction of –3.2%), without any accompanying deterioration in nutritional status.

The broader safety dataset also indicates that eplontersen is suitable for long-term use in patients with disease-related polyneuropathy, with consistent treatment benefits observed across TTR genetic variants, including early-onset Val30Met (n=54), late-onset Val30Met (n=31), and non-Val30Met (n=59) subtypes. In patients with ATTRv polyneuropathy and concomitant cardiomyopathy, eplontersen additionally demonstrated stable or improved measures of cardiac structure and function relative to historical placebo. The ongoing Phase 3 CARDIO-TTRansform trial, now fully enrolled with 1,432 randomised participants receiving eplontersen 45 mg or placebo subcutaneously every four weeks for up to 140 weeks, will further define the long-term safety profile in the cardiomyopathy setting.

The Evolving ATTR-CM Treatment Landscape After Wainua's Setback

The ATTR-CM treatment landscape encompasses both established standard-of-care agents and a growing portfolio of investigational therapies, with comparative data emerging from randomized controlled trials, meta-analyses, and real-world studies. Tafamidis, a transthyretin (TTR) stabilizer, remains the cornerstone of approved therapy, while RNA interference (RNAi) agents and antisense oligonucleotides (ASOs) represent the most advanced investigational class. Temporal trends across trial placebo cohorts also reveal a shift toward earlier-stage enrollment, complicating cross-trial efficacy comparisons.

Navigating Challenges in ATTR-CM Clinical Development

Clinical development and treatment optimization in ATTR-CM are constrained by a convergence of diagnostic, hemodynamic, pharmacological, and systemic barriers. Despite meaningful advances with disease-modifying therapies such as tafamidis, significant gaps remain across the care continuum — from timely identification to long-term management of a complex, multimorbid population.

• Diagnostic Delays and Access Inequities: ATTR-CM remains historically underdiagnosed owing to nonspecific clinical presentation and limited awareness, with challenges persisting in screening optimization. Before tafamidis approval, median time from first presentation to diagnosis was 6.2 months (IQR: 1.3–28.9) and to therapy initiation was 24.4 months (IQR: 10.7–46.8); post-approval, these reduced to 2.4 months (IQR: 0.7–21.7) and 11.8 months (IQR: 6.4–32.4), respectively, yet delays persist. Timely diagnosis (<12 months) is clinically consequential, demonstrating prolonged MACE-free survival (HR = 0.424; 95% CI: 0.22–0.81; p = 0.004), reduced heart failure hospitalization (HR = 0.40; 95% CI: 0.19–0.81; p = 0.011), and reduced all-cause mortality (HR = 0.29; 95% CI: 0.11–0.74; p = 0.009). Global access to high-cost therapies remains unequal, compounding these delays.

• Disease Progression During Therapy Gaps: Delays between diagnosis and treatment initiation — mean 127 ± 361 days in one cohort — are associated with measurable cardiac deterioration. In patients diagnosed prior to tafamidis approval, right ventricular function worsened significantly during this interval: S-velocity declined from 10.0 ± 2.2 to 9.2 ± 2.2 cm/s (p = 0.018) and TAPSE from 17.3 ± 4.7 to 15.7 ± 3.9 mm (p = 0.008), underscoring the clinical cost of treatment lag.

• Limited Efficacy in Advanced Disease Stages: Transthyretin stabilizers demonstrate benefit across all outcomes in NYHA class I/II patients, but no benefit has been identified in the NYHA class III subgroup — a finding that both reinforces the imperative of early treatment and exposes a critical unmet need in advanced disease. In a French cohort, 42 patients (33%) died or were hospitalized for cardiovascular causes with a median time-to-event of 1,050 days despite tafamidis therapy.

• Narrow Hemodynamic Therapeutic Window: Restrictive physiology and frequent autonomic dysfunction narrow the therapeutic window considerably; small perturbations in preload or afterload may precipitate hypotension, renal injury, or low-output symptoms. Loop diuretics remain foundational but require individualized dosing, preference for agents with predictable bioavailability, and closely monitored combination therapy for refractory congestion.

• Insufficient Evidence Base for Standard Heart Failure Pharmacotherapy: Randomized outcomes data for beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists are lacking in ATTR-CM specifically. Observational data indicate frequent intolerance of both beta-blockers and RAAS inhibitors. Evidence underpinning natriuresis-guided titration, outpatient IV diuresis, and hemodynamic monitoring is largely extrapolated from non-amyloid HF populations; therapy should be individualized, framed as provisional, and evaluated for net hemodynamic benefit.

• Cardiorenal Complexity and Biomarker Gaps: Cardiorenal dysfunction is prevalent in ATTR-CM and independently associated with worse outcomes. Beyond eGFR, measures such as albuminuria, cystatin C, and uromodulin may better capture glomerular and tubular vulnerability. Incorporating dynamic renal parameters — including eGFR trajectories and longitudinal albuminuria — could refine prognostic precision and improve assessment of treatment response, yet formal characterization of these biomarkers remains an unmet need.

• Outcome Heterogeneity Across Clinical Trials: Significant heterogeneity in outcome measures across trials complicates cross-study comparisons and meta-analytic inference. The trend toward enrolling patients with milder disease further challenges demonstration of clinical efficacy. Standardized progression markers represent a priority for future research infrastructure.

• Geriatric and Multidisciplinary Care Complexity: ATTR-CM disproportionately affects older adults, in whom diagnosis is inherently more challenging and has direct implications for treatment eligibility. Longer survivorship enabled by disease-modifying therapy amplifies the relevance of frailty, nutrition, mobility, caregiver burden, and early palliative integration. Prevention of age-related bias in clinical decision-making, thorough multimorbidity assessment, and cardiology–geriatric medicine collaboration are essential components of comprehensive care.

• Advanced Heart Failure Management Constraints: Advanced HF interventions are limited in this population: durable LV assist devices are generally discouraged in restrictive or biventricular phenotypes, and transplantation is reserved for carefully selected patients. Multidisciplinary management of extracardiac disease manifestations remains an ongoing challenge as survival extends.

Eplontersen's ATTR-CM Setback: A Redefinition of Efficacy

The recent announcement regarding the CARDIO-TTRansform trial for eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) marks a pivotal moment for the ATTR therapeutic landscape. While eplontersen, a ligand-conjugated antisense oligonucleotide, has demonstrated clear efficacy in reducing transthyretin (TTR) levels and improving outcomes in hereditary ATTR polyneuropathy, its inability to meet the primary efficacy endpoint in ATTR-CM underscores the profound complexity of treating the cardiac manifestations of this progressive disease.

ATTR-CM is characterized by the deposition of misfolded TTR protein in the myocardium, leading to severe heart failure. The CARDIO-TTRansform trial, notably the largest ATTR-CM study to date, aimed to assess whether eplontersen could improve a composite of cardiovascular mortality and recurrent cardiovascular events over 140 weeks, even in patients receiving standard of care, including TTR stabilizers. The failure to achieve this statistically significant benefit suggests that while TTR reduction is a foundational strategy, its impact on advanced cardiac outcomes may be limited or require earlier intervention, particularly when other TTR-stabilizing agents are already in use.

This outcome has several implications for the competitive ATTR-CM market. Tafamidis remains the cornerstone therapy, with a proven track record in prolonging survival and improving quality of life. The recent approval of acoramidis, another TTR stabilizer, further solidifies this class. Additionally, vutrisiran, a small interfering RNA (siRNA), has shown efficacy in the HELIOS-B trial and is awaiting regulatory review, positioning it as a strong contender in the gene-silencing space. Eplontersen's setback may reinforce the market dominance of these established and emerging therapies, potentially shifting the focus of future research towards novel mechanisms such as fibril clearance using monoclonal antibodies or the transformative potential of CRISPR/Cas9 gene editing, which aim to address the disease through different pathways. The challenge for future ATTR-CM therapies will be to demonstrate clear, incremental benefits beyond existing standards, especially in a disease where early diagnosis and timely intervention are increasingly recognized as critical for optimal patient outcomes.